Trinity Biotech Lands $7M From Perceptive, Regains Nasdaq Compliance
TRIB sits 64% above its 52-week low of $7.94.
Summary
Trinity Biotech secured an additional $7 million investment from Perceptive Advisors, its existing lender, and simultaneously regained compliance with Nasdaq's minimum bid price requirement. The investment follows the 1-for-30 reverse split effective July 24, 2026, which was designed to lift the share price above $1.00. Perceptive's continued capital support reduces near-term liquidity risk, though the company has a history of highly dilutive financings. The compliance restoration removes a delisting overhang, but the stock remains thinly capitalized with a market cap around $7.7 million.
At the time of this announcement, TRIB was trading at $12.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.7M. The 52-week trading range was $7.94 to $103.20. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.